ChrysCapital acquires 70.68 percent stake in Novartis India
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
ChrysCapital has completed the acquisition of a 70.68 percent controlling stake in Novartis India Limited from Swiss parent Novartis AG. This marks ChrysCapital's first majority-controlled investment in the Indian pharmaceutical sector. Dr Vikas Gupta is appointed as MD and CEO, with a new board formed including Ramesh Ramadurai as Chairperson, plus Suchita Sharma and Shashank Sinha as Independent Directors. NIL will adopt a new name and corporate identity. The company markets brands like Voveran, Calcium Sandoz, and Tegrital across pain, calcium supplementation, gynaecology, neurosciences, and transplant immunology segments.
Change of ownership from Novartis AG to ChrysCapital with new leadership. Rebranding expected. Potential strategic shifts and growth focus under private equity ownership.